-
公开(公告)号：US10899818B2
公开(公告)日：2021-01-26
申请号：US16877008
申请日：2020-05-18
IPC分类号： A01N63/00 , A61K48/00 , C07K14/725 , C07K14/53 , C07K14/54 , C07K14/705 , C12N5/0783
摘要： An immunoresponsive cell, such as a T-cell expressing (i) a second generation chimeric antigen receptor comprising: (a) a signalling region; (b) a co-stimulatory signalling region; (c) a transmembrane domain; and (d) a binding element that specifically interacts with a first epitope on a target antigen; and (ii) a chimeric costimulatory receptor comprising (e) a co-stimulatory signalling region which is different to that of (b); (f) a transmembrane domain; and g) a binding element that specifically interacts with a second epitope on a target antigen. This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.
-
公开(公告)号：US10703794B2
公开(公告)日：2020-07-07
申请号：US15749016
申请日：2016-07-28
IPC分类号： A01N63/00 , A61K48/00 , C07K14/725 , C07K14/53 , C07K14/54 , C07K14/705 , C12N5/0783
摘要： An immunoresponsive cell, such as a T-cell expressing (i) a second generation chimeric antigen receptor comprising: (a) a signalling region; (b) a co-stimulatory signalling region; (c) a transmembrane domain; and (d) a binding element that specifically interacts with a first epitope on a target antigen; and (ii) a chimeric costimulatory receptor comprising (e) a co-stimulatory signalling region which is different to that of (b); (f) a transmembrane domain; and (g) a binding element that specifically interacts with a second epitope on a target antigen. This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.
-
公开(公告)号：US10609291B2
公开(公告)日：2020-03-31
申请号：US15328715
申请日：2015-07-17
发明人： Frederic Festy , Richard Cook , Timothy Watson
IPC分类号： H04N5/235 , H04N5/353 , A61B1/06 , A61B1/00 , A61B1/05 , G02B23/20 , A61B1/045 , G02B23/24 , H04N5/225
摘要： An endoscopic apparatus and method to capture an image of in-vivo tissue with automatic exposure control. For example, the method includes capturing image data on an image sensor and analyzing an indication of brightness of each pixel to determine whether the captured image data is saturated. When the image data is saturated, the method includes reducing the exposure period by a first increment, and repeating the capturing and analyzing steps until the captured image data is not saturated. When the captured image data is not saturated, in some embodiments, the method includes analyzing the indication of brightness of each pixel compared to a threshold indicative of use of a proportion of an available dynamic range of the image sensor, and when it is determined that the threshold has not been reached, increasing the exposure period by a second increment that has a magnitude relative to the first increment.
-
公开(公告)号：US20190247396A1
公开(公告)日：2019-08-15
申请号：US16343634
申请日：2017-10-20
发明人： Paul Thomas SHARPE
IPC分类号： A61K31/506 , A61K9/00 , A61K31/404 , A61K47/42 , A61K31/433 , A61K45/06 , A61P1/02
CPC分类号： A61K31/506 , A61K6/0044 , A61K6/0067 , A61K9/0053 , A61K9/2054 , A61K31/404 , A61K31/426 , A61K31/433 , A61K38/1841 , A61K38/1875 , A61K45/06 , A61K47/42 , A61P1/02 , A61K2300/00
摘要： A pharmaceutically acceptable small molecule which inhibits GSK-3 activity, such as BIO, CHIR99021 or tideglusib; are used in the repair or regeneration of dentine. Combinations with matrix materials forming dental implants are also described and claimed.
-
公开(公告)号：US09990863B2
公开(公告)日：2018-06-05
申请号：US14774506
申请日：2014-03-10
CPC分类号： G09B23/286 , A61B6/583 , A61B2017/00716 , G01R33/56366 , G01R33/58 , G09B23/303
摘要： The invention relates to a phantom device for reproducing the fluid perfusion in a body, said device comprising a phantom organ that may be introduced into a scanner, said phantom organ comprising a housing in which are defined a plurality of fluid channels, suitably of differing cross-sectional areas; a feed tube arranged to supply liquid to a first end of all of said channels and means for collecting liquid from the other end of the channels. Alternatively or additionally, the device may comprise an element comprising a phantom heart through which fluid can flow, wherein the phantom heart comprises a first chamber representing a right atrium which is arranged to receive fluid from a fluid supply, a second chamber representing a right ventricle which receives fluid leaving said first chamber, a third chamber representing a left atrium which receives fluid leaving the second chamber and a fourth chamber representing left ventricle which receives fluid leaving the third chamber; and wherein a phantom thoracic system is interposed between the second chamber and the third chamber.Uses of the device in quality control, validation or calibration of monitoring devices such as magnetic resonance (MR) or computerized tomography (CT) scanners, in teaching or training of machine operatives or for research purposes including for research into scanners, scanning techniques or reagents such as contrast agents used in such processes, form further aspects of the invention.
-
公开(公告)号：US09381244B2
公开(公告)日：2016-07-05
申请号：US14021353
申请日：2013-09-09
发明人： Randolph Noelle
IPC分类号： A61K39/395 , C07K16/28 , A61K35/00 , A61K45/06 , A61K35/17 , C12N15/113 , A61K39/39 , A61K39/00
CPC分类号： A61K39/39566 , A61K35/17 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K45/06 , A61K47/6851 , A61K2039/505 , A61K2039/507 , A61K2039/5152 , A61K2039/5256 , A61K2039/55516 , C07K16/2827 , C07K16/2878 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2319/30 , C07K2319/32 , C12N15/113 , C12N15/1138 , C12N2310/14 , C12N2710/10034 , C12N2710/10043 , Y02A50/386 , Y02A50/41 , Y02A50/412 , A61K31/00
摘要： The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).
摘要翻译： 本公开涉及用于在有需要的患者中激活免疫应答的组合物和治疗方法。 在优选的实施方案中，本发明的方法和组合物能够拮抗VISTA的活性，VISTA是有助于免疫耐受的天然存在的“检查点”蛋白质，任选地与第二检查点途径的拮抗剂如PD-1组合。 例如，这些方法和组合物可适用于预防和治疗结肠癌或其它癌症。 在本文中证明了一种示例性的VISTA拮抗剂，特别是抗-VISTA抗体，以在体外和体内激活针对癌细胞的免疫应答，由此赋予降低肿瘤负荷的保护性抗肿瘤免疫。 另外，当将VISTA拮抗剂与第二检查点蛋白拮抗剂，特别是抗PD-1配体（PD-L1）的抗体组合使用时，观察到附加益处。
-
37.发明申请PHOSPHOCOFILIN: COFILIN CO-LOCALIZATION INTENSITY AS A PREDICTOR OF METASTATIC RECURRENCE 审中-公开磷酸铁：作为亚临床复发预测因子的COFILIN共定位强度公开(公告)号：US20150104442A1
公开(公告)日：2015-04-16
申请号：US14238253
申请日：2012-08-14
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , C07K16/2896 , G01N33/57496 , G01N2440/14 , G01N2800/56
摘要： Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin: total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided.
摘要翻译： 提供了用于确定具有肿瘤的受试者是否处于肿瘤转移风险的方法和产品。 具体地，所述方法包括检测磷酸化的椰子蛋白，以及磷酸化和非磷酸化的椰子蛋白; 定量磷酸化的cofilin，以及磷酸化和非磷酸化的cofilin的总和; 并且基于检测到的磷酸化的椰子蛋白的量：检测到的磷酸化和非磷酸化的椰子蛋白的总量，确定具有肿瘤的受试者是否可能经历肿瘤的转移。 进一步公开的是可以使用提供的方法确定的肿瘤转移的类型。
-
公开(公告)号：US08993247B2
公开(公告)日：2015-03-31
申请号：US13577978
申请日：2011-02-11
CPC分类号： G01N33/6893 , G01N2800/323
摘要： An assay for identifying an individual having or at risk of developing vascular calcification, said assay comprising obtaining a blood sample from an individual and measuring the level of a vesicular compound in a matrix vesicle present in the blood sample from said individual; wherein an increased level of said compound indicates an individual at risk of developing vascular calcification.
摘要翻译： 用于鉴定具有或有发生血管钙化风险的个体的测定法，所述测定法包括从个体获得血液样品并测量来自所述个体的血液样品中存在的基质囊泡中的囊泡化合物的水平; 其中所述化合物的水平升高表示存在发生血管钙化风险的个体。
-
公开(公告)号：US20140212906A1
公开(公告)日：2014-07-31
申请号：US14187911
申请日：2014-02-24
IPC分类号： C12Q1/37
CPC分类号： C12Q1/37 , G01N33/6848 , G01N33/721 , G01N2333/976 , G01N2560/00
摘要： A method for screening for variant peptides uses mass spectrometry (MS). A system and a kit may be used for performing the method. Proteins in a sample are digested to form a defined series of peptides. The defined series of peptides are ionized. The ionized species are subjected to collision induced dissociation. Species of known mass/charge ratio are detected to confirm the presence of the protein variant in the original sample.
摘要翻译： 用于筛选变体肽的方法使用质谱（MS）。 可以使用系统和套件来执行该方法。 将样品中的蛋白质消化以形成定义的一系列肽。 定义的肽系列被电离。 电离物质经受碰撞诱导解离。 检测已知质量/电荷比的物质以确认原始样品中蛋白质变体的存在。
-
公开(公告)号：US08658396B2
公开(公告)日：2014-02-25
申请号：US11883463
申请日：2006-02-01
IPC分类号： C12P21/04
CPC分类号： C12Q1/37 , G01N33/6848 , G01N33/721 , G01N2333/976 , G01N2560/00
摘要： A method for screening for variant peptides uses mass spectrometry (MS). A system and a kit may be used for performing the method. Proteins in a sample are digested to form a defined series of peptides. The defined series of peptides are ionized. The ionized species are subjected to collision induced dissociation. Species of known mass/charge ratio are detected to confirm the presence of the protein variant in the original sample.
摘要翻译： 用于筛选变体肽的方法使用质谱（MS）。 可以使用系统和套件来执行该方法。 将样品中的蛋白质消化以形成定义的一系列肽。 定义的肽系列被电离。 电离物质经受碰撞诱导解离。 检测已知质量/电荷比的物质以确认原始样品中蛋白质变体的存在。
-
-
-
-
-
-
-
-
-
搜索结果
341 条记录 (耗时 0.043 秒)
